Decreased Peroxisome Proliferator Activated Receptor α Is Associated with Bile Duct Injury in Cystic Fibrosis Transmembrane Conductance Regulator−/− Mice
- 1 March 2006
- journal article
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 42 (3) , 275-281
- https://doi.org/10.1097/01.mpg.0000189368.37535.42
Abstract
Primary sclerosing cholangitis (PSC) is associated with mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. As proof of concept that CFTR dysfunction plays a role in PSC, induction of colitis in cftr mice results in bile duct injury that can be prevented by pretreatment with docosahexaenoic acid (DHA). Determine whether 1) CFTR dysfunction in cftr mice through a reduction in peroxisome proliferator activated receptor (PPAR)alpha or gamma leads to bile duct injury and 2) whether DHA prevents bile duct injury through an increase in PPAR. Cftr and wild-type (WT) mice were treated with dextran sodium sulfate (DSS) to induce colitis with or without pretreatment with oral DHA. PPARalpha and gamma as well as tumor necrosis factor (TNF)alpha were analyzed in liver tissue. PPARalpha mice were also treated with DSS and histology examined. PPARgamma mRNA levels were low, with DSS suppressing mRNA levels equally in WT and cftr mice. PPARalpha levels were no different between cftr and WT litter mates by reverse-transcription polymerase chain reaction. After DSS, WT mice showed a 9.3-fold increase in PPARalpha mRNA levels and increased nuclear localization compared with no DSS (P < 0.05), with no increase seen in cftr mice. This was not caused by changes in TNFalpha. DHA treatment led to 7.0-fold increase in PPARalpha mRNA levels in cftr mice (P < 0.01). PPARalpha mice treated with DSS did not develop bile duct injury, indicating that PPARalpha alone is not sufficient to cause bile duct inflammation. DSS induced bile duct injury in cftr mice is associated with a defect in PPARalpha expression, which is reversed by DHA.Keywords
Funding Information
- National Institutes of Health (R01 DK 52765)
This publication has 32 references indexed in Scilit:
- Impaired expression of the peroxisome proliferator–activated receptor alpha during hepatitis C virus infectionGastroenterology, 2005
- Bacterial Overgrowth in the Cystic Fibrosis Transmembrane Conductance Regulator Null Mouse Small IntestineInfection and Immunity, 2004
- Activation of PPAR γ and δ by conjugated linoleic acid mediates protection from experimental inflammatory bowel diseaseGastroenterology, 2004
- Diverse regulation of NF-κB and peroxisome proliferator-activated receptors in murine nonalcoholic fatty liverHepatology, 2004
- Decreased expression of peroxisome proliferator activated receptor γ in CFTR−/− miceJournal of Cellular Physiology, 2004
- A novel PPARγ gene therapy to control inflammation associated with inflammatory bowel disease in a murine modelGastroenterology, 2003
- High yields of RNA and DNA suitable for array analysis from cell sorter purified epithelial cell and tissue populationsNature Genetics, 1999
- Ligand Selectivity of the Peroxisome Proliferator-Activated Receptor αBiochemistry, 1998
- Biliary complications of cystic fibrosis.Gut, 1992
- LIVER DISEASE AND BILEDUCT ABNORMALITIES IN ADULTS WITH CYSTIC FIBROSISThe Lancet, 1989